Duavee vs Combipatch / Climara Pro: Which Holds Up Better Long-Term for Menopause Symptom Control?

What These Two Drug Classes Actually Are

Duavee and combination estradiol patches both treat menopause, but the chemistry is genuinely different. Duavee belongs to a class called a tissue-selective estrogen complex (TSEC): it pairs a low-dose conjugated estrogen with bazedoxifene, a selective estrogen receptor modulator (SERM) that protects the endometrium without requiring a progestogen. Combination patches deliver estradiol (bioidentical to the estrogen your ovaries made) alongside a synthetic progestogen, either norethindrone acetate (NETA) in Combipatch or levonorgestrel (LNG) in Climara Pro, to provide endometrial protection the old-fashioned way.

Why does the mechanism matter for long-term durability? Because progestogen tolerance, bleeding patterns, cardiovascular risk signals, and bone response all diverge depending on which route you take.

The Tissue-Selective Estrogen Complex Concept

Bazedoxifene acts as an estrogen antagonist in the breast and endometrium while allowing conjugated estrogens to work in the hypothalamus (suppressing hot flashes) and skeleton (preserving bone). The SMART trial program across five phase-3 studies showed CE 0.45 mg/BZA 20 mg produced amenorrhea rates above 90 percent at one year, with endometrial hyperplasia rates indistinguishable from placebo.

What Combination Patches Deliver

Combipatch and Climara Pro deliver estradiol transdermally, bypassing first-pass hepatic metabolism. That bypassing is not trivial: oral estrogens stimulate hepatic production of sex-hormone binding globulin (SHBG), C-reactive protein, and clotting factors more than transdermal forms do. Continuous combined transdermal HRT data confirm that the transdermal route avoids the first-pass estrogen effect on coagulation factors, a finding relevant to women with personal or family histories of venous thromboembolism (VTE).

Hot Flash Control: How Each Option Holds Up Over Time

Both Duavee and estradiol combination patches produce clinically meaningful reductions in moderate-to-severe hot flash frequency within 12 weeks. The question of durability is where the data get thinner.

Duavee's Vasomotor Symptom Data

The SMART-3 trial randomized 664 postmenopausal women to CE/BZA or placebo and showed the CE 0.45 mg/BZA 20 mg dose reduced mean daily moderate-to-severe hot flash frequency by 74 percent from baseline at 12 weeks versus 51 percent for placebo. Sustained response data at 52 weeks in the SMART program showed continued symptom suppression without evidence of tachyphylaxis, meaning the drug did not appear to wear off over the year of follow-up.

What the data do not show: randomized controlled trial evidence beyond 2 years. The FDA approved Duavee in 2013 based on the SMART program, which ran up to 24 months. Long-term observational data beyond that window are sparse.

Combination Patch Vasomotor Data

Climara Pro reduced hot flash frequency by approximately 77 percent at 12 weeks in its key trials. Combipatch data are similar. Transdermal estradiol at doses of 0.05 mg per day has decades of clinical use, and real-world experience suggests sustained efficacy for as long as therapy continues, consistent with the known mechanism: the hypothalamic thermoregulatory center responds to estradiol in a dose-dependent and sustained manner as long as serum levels remain stable.

Patch adhesion, skin irritation, and site rotation compliance are real-world durability factors that clinical trials underestimate. Roughly 10 to 15 percent of women discontinue patches within the first year because of skin reactions, a figure not seen with oral Duavee.

Bone Protection: Two Years and Beyond

Bone is where Duavee has some of its clearest long-term data, because the SMART-5 trial specifically measured bone mineral density (BMD) as a co-primary endpoint.

SMART-5 Bone Findings

SMART-5 followed 1,843 postmenopausal women for 24 months and found that CE 0.45 mg/BZA 20 mg produced statistically significant BMD gains at the lumbar spine (plus 1.51 percent versus minus 0.86 percent for placebo) and total hip (plus 0.35 percent versus minus 1.05 percent for placebo). These BMD changes are comparable to those seen with standard-dose estrogen-progestogen therapy in trials of similar duration.

Duavee is not FDA-approved specifically for osteoporosis prevention, but the FDA label includes prevention of postmenopausal osteoporosis as an indication, alongside vasomotor symptom treatment, for women with a uterus.

Transdermal Estradiol and Bone

Estradiol is a potent anti-resorptive agent regardless of route. Transdermal estradiol 0.045 to 0.05 mg per day inhibits osteoclast activity comparably to oral conjugated estrogens at standard doses. The combination patch progestogens (NETA, LNG) are largely neutral on bone in the context of adequate estradiol, so the bone protection from Combipatch or Climara Pro comes almost entirely from the estradiol component. Women who need dedicated osteoporosis therapy (T-score below minus 2.5 with fracture risk) should have that conversation separately, because neither class replaces bisphosphonate therapy in high-risk women.

Uterine Safety Over Time: Where the Mechanisms Diverge Most

This is the most clinically important long-term difference between the two options.

Why Progestogen-Free Protection Matters for Some Women

About 20 to 30 percent of women on estrogen-progestogen therapy report progestogen-related side effects: low mood, bloating, breast tenderness, headache, and reduced libido. These side effects are not trivial. They are among the top reasons women discontinue hormone therapy within the first two years, which means the drug that was supposed to help them stops being taken. Duavee's use of bazedoxifene rather than a progestogen eliminates this source of discontinuation.

The endometrial safety data from SMART-1 through SMART-5 showed no cases of endometrial hyperplasia or cancer with CE/BZA versus placebo rates, with endometrial hyperplasia incidence below 1 percent across all treatment groups, meeting FDA-required thresholds.

Combination Patches and Endometrial Safety

Continuous combined transdermal HRT (estradiol plus daily progestogen via patch) produces amenorrhea in most women within 6 months and protects the endometrium effectively. A controlled trial of continuous combined transdermal HRT confirmed amenorrhea rates above 85 percent and no cases of endometrial hyperplasia at 12 months with continuous dosing. Irregular bleeding in the first 3 to 6 months is common and resolves in most women.

Women with a history of progestogen-sensitive depression, PMS, or PMDD may find the synthetic progestogens in patches worsen mood. Micronized progesterone (Prometrium) is sometimes substituted, though combination patches containing micronized progesterone are not commercially available in the United States.

Cardiovascular Risk: The Route-of-Administration Difference

Cardiovascular risk from hormone therapy is a nuanced topic, and route of administration is one factor that appears to matter.

Oral CE vs. Transdermal Estradiol

Oral conjugated estrogens in Duavee undergo first-pass hepatic metabolism, which increases triglycerides, SHBG, and inflammatory markers like C-reactive protein compared with transdermal estradiol. For women with pre-existing hypertriglyceridemia (triglycerides above 300 mg/dL), this hepatic stimulation can cause dangerous further elevation. Transdermal estradiol largely avoids this.

VTE risk is also lower with transdermal versus oral estrogen. Observational studies suggest the hazard ratio for VTE with oral estrogen is approximately 2.0 compared with non-users, while transdermal estradiol carries a hazard ratio closer to 1.0 to 1.2. Women with a personal history of VTE, obesity, Factor V Leiden, or prolonged immobility are generally better candidates for transdermal therapy.

Progestogen Choice and Cardiovascular Signals

Among progestogens, NETA and LNG are androgenic and may partially attenuate estradiol's favorable HDL effects. This is a theoretical concern based on lipid data; no large randomized trial has shown a difference in actual cardiovascular events between Combipatch, Climara Pro, and oral estrogen-progestogen regimens in healthy women who start therapy within 10 years of menopause, consistent with the Menopause Society's 2022 position statement on hormone therapy.

The WomanRx Route-and-Risk Framework for Choosing Between These Classes

Use this four-question clinical filter before deciding:

1. Does she have hypertriglyceridemia or a personal VTE history? If yes, transdermal patch wins.
2. Does she have significant progestogen intolerance (mood, libido, bloating on prior HRT)? If yes, Duavee wins.
3. Does she prefer weekly or twice-weekly dosing over daily pills? If yes, patch wins.
4. Does she have skin sensitivity, psoriasis, or difficulty with patch adhesion? If yes, Duavee wins.

No single answer covers every woman. These four questions narrow the field.

Breast Safety: What the Data Say for Long-Term Use

Neither option is risk-free for breast tissue with long-term use, and this deserves honest discussion.

Duavee and Breast

Bazedoxifene acts as an estrogen antagonist in breast tissue. Mammographic breast density, a surrogate for proliferative breast tissue activity, did not increase with CE/BZA in the SMART trials, in contrast to estrogen-alone or combined estrogen-progestogen therapy. Whether this translates to a long-term reduction in breast cancer risk compared with estrogen-progestogen therapy is not yet established from randomized outcome data. The SMART program was not powered or designed to detect breast cancer as an endpoint.

Combination Patches and Breast

The synthetic progestogens in combination patches, particularly NETA and LNG, have been associated with higher breast cancer risk signals than progesterone-based or progestogen-free approaches in large observational studies, including the Million Women Study cohort. The absolute excess risk for estrogen-progestogen therapy at 5 years of use is approximately 6 additional breast cancers per 10,000 women per year compared with non-users. Women should understand this number, not just hear "increased risk."

Who This Is Right For (and Who It Is Not)

Duavee Is Worth Prioritizing If You

• Have a uterus and cannot tolerate progestogens
• Have a history of progestogen-sensitive mood disorders, including PMDD or postpartum depression
• Prefer oral dosing
• Have hypertriglyceridemia (caution: CE is oral and does undergo some hepatic exposure, though the Duavee dose of CE 0.45 mg is lower than standard doses)
• Are in the early postmenopausal window (within 10 years of final menstrual period) and want bone protection alongside hot flash relief

Duavee Is Not the Right Choice If You

• Are pregnant or trying to conceive (contraindicated absolutely)
• Have active or suspected estrogen-dependent cancer
• Have a personal history of VTE and need strictly transdermal delivery
• Are on bile acid sequestrants, which reduce absorption of oral CE significantly

Combination Patches Are Worth Prioritizing If You

• Have a personal or family VTE history and prefer to avoid oral estrogen
• Want once-weekly (Climara Pro) or twice-weekly (Combipatch) dosing
• Have well-tolerated prior progestogen exposure
• Are in perimenopause with irregular cycles (patches can be adjusted more flexibly)
• Have hypertriglyceridemia at a level where oral estrogen is genuinely contraindicated

Patches Are Not the Right Choice If You

• Have significant skin sensitivity or conditions that impair transdermal absorption (severe psoriasis, thick dermal scarring at application sites)
• Have poor compliance with patch rotation and changes
• Are pregnant (estradiol-containing patches are contraindicated in pregnancy)

Pregnancy, Lactation, and Contraception: Mandatory Safety Information

Duavee is contraindicated in pregnancy. Bazedoxifene, the SERM component, is classified FDA Pregnancy Category X based on animal data showing fetal harm and the theoretical risk of fetal estrogen receptor disruption. If you are in perimenopause and still having any menstrual cycles, you must use effective contraception while on Duavee. Ovulation can occur in perimenopause even with irregular cycles.

Combination patches (estradiol plus synthetic progestogen) are also contraindicated in pregnancy. Exogenous progestogens and estrogens are not safe during pregnancy.

Lactation: Neither Duavee nor combination patches are appropriate during breastfeeding. Estrogens suppress lactation; progestogens and bazedoxifene transfer into breast milk and have not been studied for infant safety. If you are postpartum and breastfeeding, hormone therapy for menopause symptoms is not applicable to your situation, and any postpartum hormonal concerns should be addressed separately with your clinician.

Contraception note for perimenopausal women: Neither Duavee nor combination HRT patches provide contraception. If you are perimenopausal and sexually active with a chance of pregnancy, you need a separate contraceptive method. Low-dose combined oral contraceptives or a levonorgestrel IUD (which also provides endometrial protection) are options some perimenopausal women use before transitioning to HRT in postmenopause.

Switching From Duavee to a Combination Patch (or Vice Versa)

Some women will need to switch. Here is what to expect.

Switching Duavee to Combipatch or Climara Pro

The most common clinical scenario is a woman who starts Duavee and then develops concerns about oral estrogen (new triglyceride elevation found on routine labs, or a new VTE risk factor). Switching can be done the same day without a washout period: stop Duavee and apply the first patch the following morning. Expect 2 to 4 weeks of adjustment during which hot flash frequency may briefly increase as serum estradiol levels stabilize at a new equilibrium.

A key clinical point: if you are switching to a combination patch for the first time, expect possible spotting in the first 1 to 3 months as the progestogen establishes endometrial control. This is not alarming but should be documented and monitored.

Switching Combipatch or Climara Pro to Duavee

The most common reason for this switch is progestogen intolerance: mood changes, bloating, breast tenderness, or reduced libido on continuous progestogen exposure. Remove the last patch and start Duavee orally the following day. Because Duavee contains CE rather than estradiol, some women notice a subtle difference in symptom character during the first 4 to 6 weeks, including slight changes in vaginal dryness or libido, as the estrogenic milieu shifts. These usually stabilize.

Women with a history of uterine fibroids should notify their clinician before switching, because fibroids can respond differently to CE versus estradiol, and bazedoxifene's endometrial SERM activity does not address fibroid tissue directly.

Genitourinary Syndrome of Menopause (GSM): An Underappreciated Durability Gap

Neither Duavee nor combination patches are first-line for genitourinary syndrome of menopause (GSM), which includes vaginal dryness, dyspareunia, and recurrent UTIs. Systemic estrogen from either class does help GSM symptoms, but low-dose vaginal estrogen often works better for genitourinary symptoms specifically, because it delivers estradiol directly to the vaginal mucosa at very low systemic levels.

Women on Duavee who have significant GSM may add low-dose vaginal estradiol or vaginal DHEA (prasterone). Women on combination patches can do the same. The bazedoxifene in Duavee acts as an estrogen antagonist in the vagina at the systemic concentration achieved, so women on Duavee may find their vaginal symptoms less well controlled than their hot flash symptoms. This is a clinically meaningful durability gap that the SMART trials did not fully characterize.

If vaginal dryness is your primary complaint rather than hot flashes, local vaginal estrogen is likely a better starting point regardless of which systemic agent you are considering.

The Evidence Gap: What We Do Not Know

Women have been historically under-represented in long-term HRT durability trials. Almost all data for both Duavee and combination patches extend to 2 years, with real-world observational data beyond that window carrying significant confounding (women who feel well tend to continue, so long-term cohorts are a selected, healthier group).

There are no head-to-head randomized controlled trials comparing CE/BZA directly with transdermal estradiol-progestogen patches for hot flash durability, bone outcomes, or cardiovascular endpoints. Every comparison in this article is based on cross-trial synthesis of separate placebo-controlled trials, which is an important limitation. Effect sizes, baseline populations, and outcome definitions differ across trials.

Breast cancer long-term outcome data for CE/BZA are not yet available from randomized trials. The favorable mammographic density data from SMART are a mechanistic signal, not a clinical outcome.

Any claim that one option is definitively "safer" or "more durable" for breasts beyond 2 years goes beyond what current evidence supports. Be skeptical of content that states otherwise without citing specific long-term outcome trials.

Dosing Reference

| Drug | Dose | Route | Frequency | |---|---|---|---| | Duavee | CE 0.45 mg + BZA 20 mg | Oral | Daily | | Combipatch | E2 0.05 mg/d + NETA 0.14 mg/d | Transdermal | Twice weekly | | Climara Pro | E2 0.045 mg/d + LNG 0.015 mg/d | Transdermal | Once weekly |